Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with the historical ticker IKNA document the regulatory and corporate path of Ikena Oncology, Inc. as it transitioned into neBio, Inc. and shifted its Nasdaq listing to the ticker IMA. These filings include multiple Forms 8-K that describe material events such as the execution and completion of the merger with Inmagene Biopharmaceuticals, the 1-for-12 reverse stock split of Ikena common stock, and the formal change of the corporate name from Ikena Oncology, Inc. to neBio, Inc.
Within these documents, investors can find detailed descriptions of the Agreement and Plan of Merger, the two-step merger structure that made Inmagene a wholly owned subsidiary, and the resulting ownership structure of the combined company. Other filings outline the approval and implementation of new equity incentive and employee stock purchase plans that become effective after the merger, as well as the creation of contingent value rights agreements for Ikena’s legacy assets, including IK-595, and certain Inmagene assets other than -007.
Additional 8-K filings cover corporate actions such as the adoption of a 2025 Inducement Plan, the dismissal of Ernst & Young LLP as the independent registered public accounting firm and the engagement of PricewaterhouseCoopers LLP, and the mechanics and timing of the reverse stock split and new listing details on The Nasdaq Capital Market under IMA. Earlier filings and periodic reports referenced in these documents provide context on Ikena’s targeted oncology programs, including IK-930 and IK-595, and its completed collaboration with Bristol-Myers Squibb.
On Stock Titan’s filings page, users can access these SEC documents in one place and use AI-powered tools to surface key elements such as merger terms, reverse split ratios, contingent value rights mechanics, and changes in auditors or compensation plans. This helps readers quickly understand how Ikena’s historical IKNA listing evolved into neBio, Inc.’s current IMA listing and how legacy oncology and inflammatory disease assets are treated in the company’s regulatory record.
Schedule 13D/A (Am. No. 5) — ImageneBio, Inc.
OrbiMed Advisors LLC and affiliated funds updated their stake following the 25 Jul 2025 1-for-12 reverse split and PIPE financing tied to the Ikena-Inmagene merger. Outstanding shares rose to 11,181,676, cutting the group’s ownership by >1 ppt to 773,754 shares (6.92%).
Break-down: OrbiMed Private Investments VI, LP holds 753,063 shares (6.73%); Worldwide Healthcare Trust PLC, advised by OrbiMed Capital LLC, owns 135,516 shares (1.21%); OrbiMed Genesis Master Fund, LP holds 20,691 shares (0.19%). Voting/dispositive power is largely shared among OrbiMed Advisors, OrbiMed Capital GP VI LLC, and OrbiMed Genesis GP LLC.
On 25 Jul 2025 OPI VI bought 83,611 PIPE shares at $2.49 each (≈$29.90 post-split); cash came from partnership working capital. The investors secured demand, piggy-back and Form S-3 registration rights; Director David P. Bonita’s equity awards are assigned to OrbiMed. The group states no present plans for further corporate actions but may trade shares opportunistically.